Disease-related heterozygous point mutations within the SET-domain of EZH2 mainly found in lymphomas and myeloid leukemias, alter the substrate specificity of EZH2 to generate different methylation states of H3K27 which promote oncogenic progression. Here, EZH2 is linked to lymphoma.